{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:24:01Z","timestamp":1747207441588,"version":"3.40.5"},"reference-count":11,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2020,2,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Infiximab has been shown to be effective in inducing and maintaining remission\nof intestinal bowel diseases. Infiximab has been associated with many adverse events. Articular\nmanifestations are commonly reported, but they are of variable clinical expression and aetiology.\nAmong them, inflammatory bursitis has rarely been described.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Herein a case of inflammatory bursitis in a patient with Crohn\u2019s disease after switching to\nbiosimilar infliximab is reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Report::<\/jats:title>\n<jats:p>A 41-year-old man with Crohn\u2019s disease evolving from 3 years was referred to infliximab\ntherapy at a dose of 5mg\/kg because of an aggressive resistant perineal fistula. After 14 infusions of infliximab,\nthe treatment was switched to infliximab biosimilar using the same dose and frequency of administration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>The diagnosis of non-infective sub-acromial bursitis secondary to infliximab infusion was\nmade as the patient\u2019s symptoms resolved rapidly without any antibiotics. Infliximab was definitively\nstopped and adalimumab was introduced.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Forty-eight hours after the second infusion, he developed an acute onset of muscle pain and stiffness on\nboth of his shoulders. A musculoskeletal ultrasound was performed and revealed a hypoechoic widening\nof both subacromial bursae. It was more severe on the left side.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p> Musculoskeletal side effects of infliximab infusion are uncommonly reported. Among them,\nbursitis has been reported in only a few cases. Ultrasonography can help early diagnosis of bursitis. The\ntime of occurring of this reaction regarding infliximab infusion, screening of Antibodies to Infliximab\n(ATI) and clinical outcome after drug discontinuation are the main helpful arguments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886314666190904115511","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T10:26:33Z","timestamp":1567592793000},"page":"77-80","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral Sub-deltoid Bursitis in a Patient Receiving Infliximab for Crohn's Disease"],"prefix":"10.2174","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5517-1083","authenticated-orcid":true,"given":"Syrine","family":"Bellakhal","sequence":"first","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1698-517X","authenticated-orcid":true,"given":"Maissa","family":"Abbes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-4765","authenticated-orcid":true,"given":"Mohamed Taieb","family":"Jomni","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-9514","authenticated-orcid":true,"given":"Imen","family":"Abdelaali","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-8993","authenticated-orcid":true,"given":"Mehdi","family":"Charfi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-4040","authenticated-orcid":true,"given":"Mohamed Hedi","family":"Douggui","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","volume":"14","author":"Pan\u00e9s J.","year":"2017","unstructured":"Pan\u00e9s J.; Rimola J.; Perianal fistulizing Crohn\u2019s disease: Pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017,14(11),652-664","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/MEG.0000000000000098","volume":"26","author":"Hlavaty T.","year":"2014","unstructured":"Hlavaty T.; Letkovsky J.; Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2014,26(6),581-587","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=3","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. Available from:\n                     https:\/\/www.WHO-UMC.org\/media\/2768\/standardised-case-causality-assessment.pdf"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo C.A.; Busto U.; Sellers E.M.; A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981,30(2),239-245","journal-title":"Clin Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.anai.2015.06.004","volume":"115","author":"Mourad A.A.","year":"2015","unstructured":"Mourad A.A.; Boktor M.N.; Yilmaz-Demirdag Y.; Bahna S.L.; Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol 2015,115(2),143-146","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1099\/jmm.0.006809-0","volume":"58","author":"Malkin J.","year":"2009","unstructured":"Malkin J.; Shrimpton A.; Wiselka M.; Barer M.R.; Duddridge M.; Perera N.; Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet\u2019s disease. J Med Microbiol 2009,58(Pt 3),371-373","journal-title":"J Med Microbiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11845-008-0238-8","volume":"179","author":"Veerappan S.G.","year":"2010","unstructured":"Veerappan S.G.; Moinuddin G.; Kennedy M.; O\u2019Morain C.A.; Kane D.; Early diagnosis of bilateral sub-deltoid bursitis using clinic-based ultrasonography in a patient receiving infliximab therapy for ulcerative pouchitis. Ir J Med Sci 2010,179(4),597-598","journal-title":"Ir J Med Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/BTT.S96982","volume":"10","author":"Laine J.","year":"2016","unstructured":"Laine J.; Jokiranta T.S.; Eklund K.K.; V\u00e4kev\u00e4inen M.; Puolakka K.; Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-\u03b1 blockers. Biologics 2016,10,67-73","journal-title":"Biologics"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MEG.0000000000000279","volume":"27","author":"Warman A.","year":"2015","unstructured":"Warman A.; Straathof J.W.; Derijks L.J.; Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: Results of a prospective cohort study. Eur J Gastroenterol Hepatol 2015,27(3),242-248","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/MEG.0000000000000049","volume":"26","author":"Krajcovicova A.","year":"2014","unstructured":"Krajcovicova A.; Hlavaty T.; Zelinkova Z.; Letkovsky J.; Huorka M.; Delayed hypersensitivity reaction after initial dose of infliximab: A case report. Eur J Gastroenterol Hepatol 2014,26(4),485-487","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/rheumatology\/kex268","volume":"56","author":"Scherlinger M.","year":"2017","unstructured":"Scherlinger M.; Schaeverbeke T.; Truchetet M.E.; Serum sickness-like disease after switching to biosimilar infliximab. Rheumatology (Oxford) 2017,56(11),2032-2034","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:34:08Z","timestamp":1582630448000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174679\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666190904115511","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}